Results 191 to 200 of about 421,641 (311)

An updated systematic review and meta-analysis exploring the efficacy and safety of dimethyl fumarate (DMF) for patients with multiple sclerosis (MS). [PDF]

BMJ Neurol Open
Ali HT, Yousef AM, El-Farargy SH, Abdelmonhem AM, Abouda DA, Mahmoud AM, Elsayed AA, Hassaan HK, Afifi AM.   +8 more
europepmc   +1 more source

Evaluation of MoveSmart MS - an online structured exercise, Social Cognitive Theory-based behavioural coaching and peer support programme - on anxiety in multiple sclerosis

Austin Fahy, Susan Coote, Rebecca Maguire   +2 more
openalex   +1 more source

Readiness of Patients with Multiple Sclerosis (MS) to Use Mobile Health Technology

, 2017
Reza Abbasi, Leila Ahmadian, Nazanin Jannati, Mohsen Baloochi, Misagh Zahiri Esfahani   +4 more
openalex   +2 more sources

The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study (Preprint)

, 2020
Nils-Henning Neß, Rocco Haase, Raimar Kern, Dirk Schriefer, Benjamin Ettle, Christian Cornelissen, Katja Akguen, Tjalf Ziemssen   +7 more
openalex   +1 more source

Cognitive impairment, fatigue and depression in multiple sclerosis: Is there a difference between benign and non-benign MS?

, 2023
Hans Bogaardt, Daniel Golan, Marissa A. Barrera, Stacie Attrill, Olivia Kaczmarek, Myassar Zarif, Barbara Bumstead, Marijean Buhse, Jeffrey Wilken, Glen M. Doniger, Laura M. Hancock, Iris‐Katharina Penner, June Halper, Sarah A. Morrow, Thomas J. Covey, Mark Gudesblatt   +15 more
openalex   +1 more source

Rating neurologic impairment in multiple sclerosis

Neurology, 1983
J. Kurtzke
semanticscholar   +1 more source

Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real‐World Evidence

Annals of Neurology, EarlyView.
Objective The objective of this study was to compare the long‐term safety profiles of ocrelizumab and rituximab in persons with multiple sclerosis (MS). Methods Using retrospective data from the University of California (UC) Health System, we simulated a target clinical trial. The primary cohort from UC San Francisco (UCSF) and a validation cohort from
Gabriel Cerono, Bruce A.C. Cree, Stephen L. Hauser, Sergio E. Baranzini   +3 more
wiley   +1 more source

The Role of E2F Transcription Factor 1 Protein in Multiple Sclerosis (MS): A Comparative Study of Serum Levels in MS Patients and Healthy Controls. [PDF]

Cureus
Kılıçparlar Cengiz E, Ekmekyapar Fırat Y, Onur E, Denkçeken T.   +3 more
europepmc   +1 more source

Strengthening Mental Abilities with Relational Training (SMART) in multiple sclerosis (MS): study protocol for a feasibility randomised controlled trial. [PDF]

Pilot Feasibility Stud, 2022
Golijani-Moghaddam N, Dawson DL, Evangelou N, Turton J, Hawton A, Law GR, Roche B, Rowan E, Burge R, Frost AC, das Nair R.   +10 more
europepmc   +1 more source

Pro‐Inflammatory c‐Met+ CD4 T Cells in Multiple Sclerosis

Annals of Neurology, EarlyView.
Objective Hepatocyte growth factor (HGF) binds exclusively the c‐Met surface receptor, and the HGF/c‐Met axis regulates T cell function in autoimmune diseases. We analyzed c‐Met expression on human CD4 T cells in the blood and cerebrospinal fluid (CSF) from patients with multiple sclerosis (MS) versus non‐inflammatory neurological disease (NIND), to ...
Gautier Breville, Mahdia Benkhoucha, Ayman Rezk, Ngoc Lan Tran, Isis Senoner, Amit Bar‐Or, Patrice H. Lalive   +6 more
wiley   +1 more source